

81. (New) The method of claim 14, wherein the animal is a human.

82. (New) The liposome of claim 1, wherein  $Z^1$  is OH or a conversion-inhibiting group selected from the group consisting of  $-X^1$ ,  $-OX^1$ ,  $-X^2X^3$  and  $-OX^2X^3$ .

83. (New) The liposome of claim 1, wherein  $R^2$  is an alkyl chain.

84. (New) The liposome of claim 1, wherein  $R^1$  is  $CH_3(CH_2)_{12}$ .

85. (New) The liposome of claim 1, wherein  $Y^1$  is  $-CH=CH-$ .

86. (New) The liposome of claim 1, wherein  $Y^2$  is H.

87. (New) The liposome of claim 1, wherein  $Y^3$  is  $-C(O)R^2$ .

88. (New) The liposome of claim 1, wherein  $Z^1$  is OH.

89. (New) The liposome of claim 88, wherein  $Z^2$  is a group having the formula  $-X^2X^3$  or  $-O-X^2X^3$ .

90. (New) The liposome of claim 89, wherein  $Z^2$  is  $-OC(O)CH_3$ ,  $-OC(O)CH_2CH_2CH_3$ ,  $-OC(O)CH(CH_3)CH_3$  or  $-OSi(CH_3)_2C(CH_3)_3$ .

91. (New) The liposome of claim 90, wherein  $Z^2$  is  $-\text{OSi}(\text{CH}_3)_2\text{C}(\text{CH}_3)_3$ .

92. (New) The liposome of claim 88, wherein  $Z^2$  is a group having the formula  $-\text{X}^1$  or  $-\text{OX}^1$ .

93. (New) The liposome of claim 1, wherein  $Z^1$  is  $-\text{X}^1$ ,  $-\text{OX}^1$ ,  $-\text{X}^2\text{X}^3$  and  $-\text{OX}^2\text{X}^3$ .

*E<sup>1</sup> concl.*  
94. (New) The liposome of claim 93, wherein  $Z^1$  is  $-\text{OC}(\text{O})\text{CH}_3$ ,  $-\text{OC}(\text{O})\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{OC}(\text{O})\text{CH}(\text{CH}_3)\text{CH}_3$  or  $-\text{OSi}(\text{CH}_3)_2\text{C}(\text{CH}_3)_3$ .

95. (New) The liposome of claim 1, wherein the compound having the formula  $\text{R}^1-\text{Y}^1-\text{CHZ}^1-\text{CH}(\text{NY}^2\text{Y}^3)-\text{CH}_2-\text{Z}^2$  is  $\text{CH}_3-(\text{CH}_2)_{12}-\text{CH}=\text{CH}-\text{CH}_2\text{Z}^1-\text{CH}(\text{NH}\text{Y}^3)-\text{CH}_2\text{Z}^2$ .

96. (New) The liposome of claim 95, wherein  $Z^1$  is OH and  $\text{Y}^3$  is a group having the formula  $-\text{C}(\text{O})\text{R}^2$ .

97. (New) The liposome of claim 96, wherein  $\text{Y}^3$  is  $-\text{C}(\text{O})(\text{CH}_2)_4\text{CH}_3$ .

98. (New) The liposome of claim 87, wherein  $Z^2$  is  $-\text{OSi}(\text{CH}_3)_2\text{C}(\text{CH}_3)_3$ ,  $-\text{OSi}(\text{PO}_4)_2\text{C}(\text{CH}_3)_3$ ,  $-\text{C}(\text{O})\text{CH}_3$  or  $-\text{OC}(\text{O})\text{CH}_2\text{CH}_2\text{CH}_3$ .

99. (New) The liposome of claim 1, wherein the bilayer comprises at least about 10 mole percent of the compound having the formula  $\text{R}^1-\text{Y}^1-\text{CHZ}^1-\text{CH}(\text{NY}^2\text{Y}^3)-\text{CH}_2-\text{Z}^2$  - -